arrow
J

Joseph F. Standing

stellenbosch university
H指数:34
被引数:4,202

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study

评价阿达木单抗在银屑病中的治疗药物监测策略:一项前瞻性药代动力学-药效学研究

2026-04-300
OAAI
Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients
2026-04-239
PRE
Population pharmacokinetic/pharmacodynamic modelling to evaluate favipiravir in combination with lopinavir-ritonavir in patients with COVID-19

基于群体药代动力学/药效动力学模型评估法匹拉韦与洛匹那韦-利托那韦联合用药在COVID-19患者中的效果

2026-03-010
OAAI
Pharmacokinetic-pharmacodynamic modelling of risankizumab using chronic plaque psoriasis real-world data

利用慢性斑块状银屑病真实世界数据进行的 risankizumab 药代动力学-药效动力学建模

2026-02-010
OAAI
Systematic review of antimicrobial pharmacokinetic/pharmacodynamic indices in murine thigh and hollow fibre dose fractionation studies analysed with a standard method

系统评价:使用标准方法分析小鼠大腿和空心纤维剂量分割研究中抗菌药物药代动力学/药效学指标

2025-12-010
PRE
Elesclomol-copper therapy improves neurodevelopment in two children with Menkes disease

Elesclomol-铜疗法改善了两位Menkes病患儿的神经发育。

2025-10-010
OAAI
Pharmacokinetic and Pharmacodynamic Modeling of Clonidine and Midazolam for Sedation in Pediatric Intensive Care

氯胺酮和咪达唑仑用于儿科重症监护镇静的药代动力学和药效动力学建模

2025-10-010
OAAI
A Viroimmunologic Model to Characterize the Antiviral Effect of Molnupiravir in Outpatients Infected With SARS-CoV-2: Implication for Treatment Duration

一种病毒免疫学模型,用于表征莫纳皮拉韦在感染SARS-CoV-2的门急诊患者中的抗病毒作用:对治疗持续时间的启示

2025-04-010
PRE
Personalizing Biologic Therapy in Psoriasis: Development, Validation, and User Testing of a Precision-Dosing Dashboard

银屑病生物制剂疗法的个性化:精准给药仪表盘的开发、验证和用户测试

2025-02-190
OAAI